医学风险婴儿轮状病毒疫苗接种非特异性效果评估
该研究基于准实验前后对照设计,比较医学风险婴儿接种与未接种轮状病毒疫苗队列至18月龄的非特异性效果。分析纳入496名未接种和719名接种婴儿,结果显示轮状病毒疫苗对急性住院、急性呼吸道疾病和湿疹无或极小非特异性影响。
要点
- 医学风险婴儿中轮状病毒疫苗对急性住院无显著非特异性保护或风险
- 对急性呼吸道疾病和湿疹的调整率比均接近1且无统计学意义
- 研究不支持轮状病毒疫苗在医学风险婴儿中产生明显非特异性效果
核心结论
- 医学风险婴儿接种轮状病毒疫苗对急性住院、急性呼吸道疾病或湿疹无或极小非特异性效果。
研究设计与样本
- 准实验前后对照研究,比较阶梯式实施医院风险组轮状病毒疫苗接种项目前后的婴儿队列。
主要发现
- 分析纳入496名未接种和719名接种的医学风险婴儿。
关键数值与推荐
- 非特异性效果结局通过每月问卷前瞻性收集,包括急性住院(排除急性胃肠炎)、急性呼吸道疾病月发病率和湿疹。
- 采用时间-事件分析和负二项回归评估至少一剂轮状病毒疫苗接种的效果。
临床怎么用
- 在医学风险婴儿中,轮状病毒疫苗接种的非特异性效应不显著,临床决策应主要基于其特异性预防轮状病毒胃肠炎的效果。
局限性
- 准实验设计可能受未测量混杂因素影响;非特异性效果结局依赖问卷报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO recommends research into non-specific effects of vaccination. For rotavirus vaccines, these have not yet been well established. We studied non-specific effects up to 18 months of age using data from a quasi-experimental before-after study comparing cohorts of rotavirus vaccinated and unvaccinated infants with medical risk conditions. METHODS: Infants were enrolled at six weeks of age before and after a stepped-wedge implementation of a hospital-based risk-group rotavirus vaccination program. Other infant vaccinations were administered according to the Dutch National Immunization Program and similar in both cohorts. Non-specific effect outcomes were prospectively collected using monthly questionnaires and included acute hospitalization (excluding for acute gastroenteritis), monthly incidence of acute respiratory illness and eczema. We used time-to-event analysis and negative binomial regression to assess the effect of at least one dose of rotavirus vaccination for each of these outcomes. Findings The analysis included 496 rotavirus unvaccinated and 719 vaccinated medical risk infants. In total, 1067 (88%) were premature, 373 (31%) small for gestational age and 201 (17%) had a congenital pathology. The adjusted hazard ratio for first acute hospitalization was 0·91 (95 %CI 0·76;1·16) for rotavirus vaccinated versus unvaccinated infants. Adjusted incidence rate ratio for acute respiratory illness was 1·05 (95 %CI 0·96;1·15) and for eczema 0·89 (95 %CI 0·69;1·15). CONCLUSION: The results suggest no, or minimal non-specific effects from rotavirus vaccination on acute hospitalization, acute respiratory illness or eczema in medical risk infants. TRIAL REGISTRATION: as NTR5361 in the Dutch trial registry, www.trialregister.nl.
引用
- van Dongen JAP, Rouers EDM, Bonten MJM, et al. Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants. Vaccine. 2021. PMID: 34507856. doi:10.1016/j.vaccine.2021.08.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。